<?xml version="1.0" encoding="UTF-8"?>
<ref id="B40">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Serra</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Markman</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Scaltriti</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Eichhorn</surname>
    <given-names>P. J.</given-names>
   </name>
   <name>
    <surname>Valero</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Guzman</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2008</year>). 
  <article-title>NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.</article-title>
  <source>
   <italic>Cancer Res.</italic>
  </source>
  <volume>68</volume>
  <fpage>8022</fpage>â€“
  <lpage>8030</lpage>. 
  <pub-id pub-id-type="doi">10.1158/0008-5472.can-08-1385</pub-id>
  <?supplied-pmid 18829560?>
  <pub-id pub-id-type="pmid">18829560</pub-id>
 </mixed-citation>
</ref>
